Hepatocellular adenoma surgery

Hepatocellular adenoma Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Hepatocellular adenoma from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Study of Choice
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
X-ray
Echocardiography and Ultrasound
CT scan
MRI
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Hepatocellular adenoma surgery On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Hepatocellular adenoma surgery All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Hepatocellular adenoma surgery
CDC on Hepatocellular adenoma surgery
Hepatocellular adenoma surgery in the news
Blogs on Hepatocellular adenoma surgery
Directions to Hospitals Treating Hepatocellular adenoma
Risk calculators and risk factors for Hepatocellular adenoma surgery

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-In-Chief: Cafer Zorkun, M.D., Ph.D. [2] Zahir Ali Shaikh, MD[3]

Overview

There is no specific medical therapy for the hepatocellular adenomas. The wait and watch policy is recommended for hepatocellular adenoams <5cm following cessation of offending drugs (OCPs) and no further growth detected. Annual followup is scheduled with MRI or ultrasound until menopause.

Hepatocellular adenoma surgery

• There is no specific medical therapy for the hepatocellular adenoma.
• Historically, hepatocellular adenomas were treated with a wait and watch policy, with surgical intervention recommended for larger (>5cm) tumors.
• In asymptomatic female patients of hepatocellular adenomas , the first step is to stop the offending drug (OCPs) and check adenoma size on followup.
• The wait and watch policy is recommended when hepatocellular adenomas are <5cm or regress (to <5cm) following cessation of offending drug (OCPs) and no further growth detected.
• An yearly followup with MRI or ultrasound is scheduled for patients untill menopause.

{{{ A01 }}}

{{{ B01 }}}

{{{ B02 }}}

{{{ C01 }}}

{{{ C02 }}}

{{{ C03 }}}

{{{ C04 }}}

{{{ D01 }}}

{{{ D02 }}}

{{{ D03 }}}

{{{ D04 }}}

{{{ E01 }}}

{{{ E02 }}}

{{{ F01 }}}

{{{ F02 }}}

{{{ F03 }}}

{{{ F04 }}}

{{{ F05 }}}

References

Template:WikiDoc Sources